^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:HER2 Positive Breast Cancer
    Drug:capecitabine (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/27/2023
    Excerpt:
    Breast cancer....HER2-Positive Regimens...Capecitabine 750 mg/m² PO twice daily on days 1–14
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients

    Excerpt:
    ...- Early stage operable HER2-positive primary breast cancer...
    Trial ID:
    SMART
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

    Excerpt:
    ...- Must have received ≥ 1 prior trastuzumab (Herceptin®)-containing regimen (unless there is a contraindication) if tumor is HER2 positive (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization [FISH])...
    Trial ID:
    NCT00450515
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer

    Excerpt:
    ...Pathological confirmation of triple negative or Her-2 positive or with more than 4 axillary lymph node metastasis 5....
    Trial ID:
    NCT01662128
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Exploratory clinical study of Inetetamab + Pyrotinib + Capecitabine in the neoadjuvant treatment of HER2-positive breast cancer that is not sensitive to the initial treatment of trastuzumab

    Excerpt:
    ...Pathological examination confirmed that it is HER-2 positive invasive breast cancer; (HER2 positive is defined as immunohistochemistry (IHC) 3+ or IHC 2+ and further application of in situ hybridization (ISH) detection is HER2 gene amplification), regardless of Hormone receptor status (ER and PR); 3. ...
    Trial ID:
    ChiCTR2100046944
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

    Excerpt:
    ...Histopathological and/or cytological confirmed Her2-positive locally advanced or metastatic breast cancer (IHC3+, or IHC2+ and ISH+) 7....
    Trial ID:
    NCT05575804
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer

    Excerpt:
    ...Objective to evaluate the intracranial tumor progression time of piratinib and capecitabine combined with brain radiotherapy for HER2 positive breast cancer patients with brain metastasis`Time of intracranial tumor progression...
    Trial ID:
    NCT04767828
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A Phase II Study of pyrotinib combined with capecitabine plus anlotinib for HER2-Positive Metastatic Breast Cancer

    Excerpt:
    ...Patients with recurrent/metastatic breast cancer confirmed by pathological examination with positive HER2 expression; Positive expression of HER2 refers to those whose HER2 is positive by standard immunohistochemical staining (IHC) and/or fluorescence in situ hybridization (FISH) (verified by the researchers in the test center); 3. ...
    Trial ID:
    ChiCTR2100045962
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

    Excerpt:
    ...The patient has been confirmed to be HER2 positive....
    Trial ID:
    NCT03684863
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Maintenance treatment of capecitabine in patient with HER 2-positive and triple negative breast cancer: a randomized, open label, blank controlled, multicenter trial

    Excerpt:
    ...Breast cancer subtypes are HER-2 positive or triple negative breast cancer, and not accept the anti-target therapy; 8. ...
    Trial ID:
    ChiCTR1800019987